Here's My Top Growth Stock to Buy Right Now
Hims & Hers' unique, brand-driven strategy can help it establish a moat in the competitive telehealth industry. Over the long term, the company can leverage user data and artificial intelligence to generate shareholder value.
Is This Telehealth Stock a Buy After the Recent Pullback?
Hims & Hers Health, Inc. NYSE: HIMS is a prominent player in the telehealth sector, which is part of the larger healthcare sector. The company has garnered significant attention from investors due to its remarkable rise in the stock market.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.11, indicating a +1.18% shift from the previous trading day.
2 Incredibly Cheap Growth Stocks to Buy Now
These companies are on different growth trajectories, but each has something to offer long-term investors. Hims & Hers is increasing subscribers and revenue rapidly, while profitability is expanding.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Jim Cramer on Hims & Hers Health stock: 'I bet the business stays strong'
CNBC's Jim Cramer gave his take on the Hims & Hers Health, a digital health and wellness platform, saying it might be worth opening a position in the stock now that it's pulled back somewhat from its highs. Hims & Hers offers telehealth services and direct-to-consumer treatments for erectile dysfunction and hair loss, and it just announced it would start selling compounded GLP-1 weight loss injections.
Are Medical Stocks Lagging Hims & Hers Health (HIMS) This Year?
Here is how Hims & Hers Health, Inc. (HIMS) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Is Hims & Hers Stock a Buy After Short Report?
There are valid points in the short report, but it may present a buying opportunity for long-term investors.
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.
Hims & Hers Stock Drops 12.8% After Short Report
A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock.
Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report
Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes research on stocks through Hunterbrook Media while sometimes taking a position in the same stock through its hedge fund affiliate, Hunterbrook Capital.
